Corcept Therapeutics announced the initiation of BELLA, a Phase 2 trial evaluating relacorilant in combination with nab-paclitaxel and bevacizumab for patients with platinum-resistant ovarian cancer. This new trial aims to explore additional treatment options for women facing this aggressive disease.
The BELLA study is designed as a single-arm, open-label trial with a planned enrollment of 90 women across approximately 50 sites in North America, Europe, and Asia-Pacific. This builds on the positive results seen in the pivotal Phase 3 ROSELLA trial, which demonstrated improved progression-free and overall survival with relacorilant plus nab-paclitaxel.
By investigating a triple combination, Corcept is seeking to further enhance the efficacy of cortisol modulation in oncology. This expansion of the clinical program underscores the company's strategy to develop differentiated therapies and broaden the application of its selective glucocorticoid receptor antagonist platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.